Still investigational
Retatrutide remains in clinical development. It is not an approved weight-loss medication and is not available as routine clinical treatment.
Investigational triple agonist research
Retatrutide for Weight Loss
Retatrutide is an investigational once-weekly triple agonist being studied for obesity. It is not FDA approved. WellForm MD can help you understand the research and the weight-loss options available today.
- Investigational—not FDA approved
- Physician-reviewed research context
- Current weight-loss options available now
What it is
Retatrutide is a once-weekly injectable being studied as a GLP-1/GIP/glucagon triple agonist.
Where it stands
It remains investigational and is not FDA approved. Lilly has reported Phase 3 results and plans a later regulatory submission.
What you can do now
Talk with a physician about the research, emerging options, and currently available medical weight-loss care.
The next generation of weight loss medication?
Why retatrutide is attracting so much attention
Retatrutide is one of the most closely watched medications currently being studied for obesity and weight management.
Unlike today’s GLP-1 medications, retatrutide targets three hormone receptors at the same time: GLP-1, GIP, and glucagon. For this reason, it is commonly described as a triple agonist.
Early and Phase 3 clinical trial results have generated significant interest because of the amount of weight loss observed in study participants.
At WellForm MD, we closely follow emerging obesity treatments so our patients can understand what is coming, what the research actually shows, and how new medications may eventually fit into comprehensive medical weight management.
Retatrutide is still investigational and is not currently FDA approved. WellForm MD is not offering retatrutide as an FDA-approved prescription treatment.
If you are interested in retatrutide, want to understand the research, or would like to discuss the weight loss treatments currently available to you, our medical team can help.
A different mechanism
One molecule is designed to activate GLP-1, GIP, and glucagon receptors rather than one or two of those pathways.
What is retatrutide?
An investigational once-weekly medicine from Eli Lilly
Retatrutide is being developed for obesity and other metabolic conditions. Its scientific name during development has also been LY3437943.
Retatrutide is different from traditional GLP-1 medications because one molecule activates three different hormone receptors: GLP-1 (glucagon-like peptide-1), GIP (glucose-dependent insulinotropic polypeptide), and glucagon.
That is why retatrutide is referred to as a triple hormone receptor agonist, or simply a triple agonist.
You may occasionally see retatrutide described online as a “GLP-3.” That is not a formal scientific drug category. Retatrutide is more accurately described as a GLP-1/GIP/glucagon triple agonist.
How does retatrutide work?
Three metabolic pathways in one investigational molecule
Retatrutide is designed to act on several metabolic pathways simultaneously. Mechanism helps explain the scientific interest. It does not establish individual results or current availability.
- 01
GLP-1
GLP-1 receptor activity can reduce appetite, increase fullness, slow gastric emptying, and support blood sugar regulation. This is a major pathway targeted by medications such as semaglutide.
- 02
GIP
GIP receptor activity may work with GLP-1 signaling to influence appetite, insulin response, glucose regulation, and energy metabolism. Tirzepatide already combines GIP and GLP-1 activity.
- 03
Glucagon
Retatrutide adds the glucagon receptor. Researchers are studying whether carefully balanced glucagon activity can increase energy expenditure and contribute to greater overall metabolic effects.
Retatrutide therefore represents a different approach from medications that target only one or two of these pathways.
How much weight did people lose?
Phase 3 averages that explain the public interest
The weight loss seen in retatrutide clinical trials is one of the main reasons the medication has attracted so much attention. These are study averages—not predictions of what any individual person would lose.
28.3%
TRIUMPH-1 at 80 weeks
Adults without diabetes on the highest studied 12 mg dose had an average 28.3% reduction, about 70.3 pounds, under the efficacy estimand.
30.3%
BMI ≥35 extension at 104 weeks
Among participants with a starting BMI of at least 35 who continued into a longer study period, average weight loss reached approximately 30.3%.
4 / 9 / 12 mg
Doses studied in major obesity trials
Researchers used gradual dose-escalation schedules. Trial doses are not individual treatment recommendations.
Some participants lost less. Some lost more. Response can be affected by starting weight, tolerance, dose, nutrition, activity, sleep, medical conditions, other medications, genetics, and treatment duration. Medical weight loss should never be reduced to simply choosing a medication.
Retatrutide Phase 3 results
Positive topline findings across several TRIUMPH studies
Retatrutide has now produced positive results across several Phase 3 studies. The research program continues to evaluate both potential benefits and safety.
TRIUMPH-1
- Adults with obesity or overweight without diabetes.
- Up to approximately 28.3% average weight loss at 80 weeks on 12 mg.
- Approximately 30.3% average weight loss at 104 weeks in the BMI ≥35 extension population.
TRIUMPH-2
- Adults with obesity or overweight and type 2 diabetes.
- Up to approximately 20.8% average weight loss at 80 weeks.
- Improvements in A1C were also observed, up to an average of 1.6%.
TRIUMPH-3
- Adults with severe obesity and established cardiovascular disease, with or without type 2 diabetes.
- Up to approximately 22.6% average weight loss at 80 weeks.
TRIUMPH-4
- Adults with obesity or overweight and knee osteoarthritis.
- Up to approximately 28.7% average weight loss at 68 weeks.
- Significant improvements in knee osteoarthritis pain were also reported.
Retatrutide is also being studied for several obesity-related and metabolic conditions, including obstructive sleep apnea. These figures come from Lilly Phase 3 topline releases and remain subject to full peer-reviewed publication and regulatory review.
Is retatrutide better than semaglutide?
Separate trials are not the same as a head-to-head answer
There is considerable interest in comparing retatrutide with semaglutide. Semaglutide primarily targets the GLP-1 receptor. Retatrutide targets GLP-1, GIP, and glucagon.
Different mechanisms
What the numbers can show
The Phase 3 weight-loss results reported with retatrutide have been impressive. That does not automatically make one medicine superior for a particular person.
- Semaglutide is a GLP-1 receptor agonist with approved clinical use.
- Retatrutide is a triple agonist and remains investigational.
- Trial averages describe study populations, not individual forecasts.
Comparison boundary
What they cannot prove
Numbers from separate clinical trials should not automatically be treated as a direct head-to-head comparison.
- Different studies can involve different patient populations.
- Treatment durations, designs, lifestyle programs, and endpoints can differ.
- Dropout rates and study conduct also change how percentages should be read.
The best way to determine whether one treatment is superior to another is through appropriately designed comparative research.
Retatrutide vs. tirzepatide
The glucagon pathway is the major scientific difference
This may eventually become one of the most important comparisons in obesity medicine. Tirzepatide targets GIP and GLP-1. Retatrutide targets GIP, GLP-1, and glucagon.
| Feature | Tirzepatide | Retatrutide |
|---|---|---|
| GLP-1 receptor | Yes | Yes |
| GIP receptor | Yes | Yes |
| Glucagon receptor | No | Yes |
| Receptor type | Dual agonist | Triple agonist |
| Currently FDA approved for obesity | Yes, as Zepbound | No |
| Development stage | Available clinically | Phase 3 / investigational |
The strong weight loss reported in retatrutide trials makes this comparison very interesting. Percentages from separate clinical trials are not the same as a direct head-to-head trial.
Is retatrutide a GLP-1?
Yes—but a GLP-1/GIP/glucagon triple receptor agonist is more accurate
Retatrutide activates the GLP-1 receptor while also activating GIP and glucagon receptors.
A more accurate description is GLP-1/GIP/glucagon triple receptor agonist.
This triple mechanism is what distinguishes retatrutide from currently available medications such as semaglutide and tirzepatide.
Is retatrutide FDA approved?
No. It remains investigational and is not available for routine care
Until regulatory review is complete, retatrutide should be viewed as an emerging obesity treatment rather than an approved weight-loss medication.
Retatrutide is not currently FDA approved. It remains an investigational medication undergoing clinical development.
Lilly has reported results from several Phase 3 studies. In July 2026, Lilly said it plans to submit a Biologics License Application in the first quarter of 2027 after completing its manufacturing and quality-control package. That is a planned submission, not an approval date.
There is not yet a confirmed public launch date. Even after submission, timing depends on the regulatory review process. No one can currently provide a guaranteed date when retatrutide will become commercially available.
At WellForm MD, we are closely monitoring the research and will continue updating our patients as the evidence and regulatory status develop.
No guaranteed launch date
A planned 2027 submission does not mean approval or availability in 2027. Review can take additional time and may or may not result in approval.
Stay connected
If you are interested in retatrutide, you can contact WellForm MD and stay connected as the science and treatment landscape develop.
What are the side effects of retatrutide?
Gastrointestinal effects have been the most commonly reported so far
Because retatrutide affects incretin pathways similar to other medications used in obesity treatment, gastrointestinal symptoms have been among the most commonly reported side effects in clinical trials.
Review before starting
- Side effects can vary according to the individual and the dose.
- Researchers continue to evaluate retatrutide’s overall safety profile as the Phase 3 development program progresses.
- Long-term treatment decisions should always consider more than the amount of weight lost.
- The goal is effective weight loss with a treatment that is also safe, tolerable, nutritionally appropriate, and sustainable.
Common treatment issues
- Nausea
- Diarrhea
- Vomiting
- Constipation
- Reduced appetite
Contact the care team
If you have questions about these trial findings or about currently available medical weight-loss options, contact WellForm MD rather than trying to interpret research headlines on your own.
Lilly’s TRIUMPH-1 topline release reported that the types of adverse events were generally consistent with other incretin-based therapies. This page does not reproduce a complete safety list and is not prescribing information.
Why is retatrutide getting so much attention?
Large trial averages are only one part of the picture
The weight-loss results have been unusually large. Impressive trial results still leave important questions about long-term use, safety, and the right patient.
- 1
A field that has already changed
GLP-1 medications changed obesity medicine. Tirzepatide pushed the field further with dual GIP and GLP-1 activity.
- 2
A third pathway under study
Retatrutide is investigating whether targeting three metabolic hormone pathways simultaneously can take obesity treatment another step forward.
- 3
Questions still being answered
Continued evaluation is needed for long-term effectiveness, side effects, discontinuation, muscle preservation, nutrition, weight maintenance, metabolic outcomes, cardiovascular outcomes, and patient selection.
- 4
More choices, not one replacement
Retatrutide will probably not simply replace every medicine that came before it. The future of obesity medicine will likely involve more treatment choices, not one medication for everyone.
Some patients may do extremely well with semaglutide. Others may respond better to tirzepatide. Oral medications are also emerging. The goal should always be to match the treatment to the patient rather than chasing whichever medication has the newest headline.
Muscle, regain, and future candidacy
Powerful weight loss still needs comprehensive medical management
Significant weight loss can involve loss of both fat mass and lean mass. Obesity is generally a chronic disease, and weight can return when effective treatment is withdrawn.
Retatrutide and muscle loss
- Patients using powerful obesity medications should pay attention to more than total pounds lost.
- WellForm MD includes attention to adequate nutrition, protein intake, resistance exercise, body composition, strength, hydration, and sustainable lifestyle changes.
- The more powerful weight-loss medications become, the more important comprehensive medical management becomes.
- Weight loss should improve health—not simply produce a smaller number on the scale.
Can weight come back?
- Medications can help regulate biological pathways involved in appetite, fullness, food intake, and metabolism.
- When effective treatment is withdrawn, some of those biological pressures can return.
- Retatrutide is still being studied, so its long-term maintenance strategy will continue to become clearer as additional evidence develops.
- This is one reason we focus on sustainable nutrition, activity, muscle preservation, behavioral changes, and long-term weight management rather than thinking of medication as a temporary shortcut.
Who might eventually be a candidate?
- Because retatrutide is not yet approved, there is not currently an approved patient-selection framework for routine clinical use.
- Its Phase 3 research program has included people with obesity or overweight and conditions such as type 2 diabetes, cardiovascular disease, knee osteoarthritis, and obstructive sleep apnea.
- If retatrutide receives regulatory approval, the final indication and prescribing criteria will determine exactly who may be an appropriate candidate.
What WellForm MD can discuss now
- What current research shows and where retatrutide is in development.
- How it differs from current GLP-1 medications.
- What treatments are available today and which weight-management approach may make sense for you.
- How to prepare for the rapidly changing future of obesity treatment.
There is a tremendous amount of information about new weight-loss medications online. It can be difficult to separate clinical evidence, preliminary research, marketing, social media claims, and real medical guidance.
Useful next reading
Understand current care while the research continues
These pages explain the treatments, nutrition questions, and physician-led program available today.
Medical weight loss
The current physician-supervised program, inclusions, and how prescription treatment may fit after evaluation.
Continue
GLP-1 weight-loss care
A class-level guide to ingredients, brands, formulations, and why treatment decisions require individual evaluation.
Continue
Tirzepatide
The current dual GIP/GLP-1 option most often compared with retatrutide, including evidence boundaries and care.
Continue
Semaglutide
A GLP-1-only path with injectable and oral brand forms, different evidence, and a different treatment routine.
Continue
Zepbound
Brand-specific expectations for FDA-approved tirzepatide used in obesity care.
ContinueGLP-1 diet WebBook
Practical nutrition guidance for people using or considering GLP-1 medicines.
ContinueMuscle-preservation WebBook
How to think about lean mass while losing a large amount of weight.
ContinueWeight-loss plateau WebBook
How to tell scale noise from a true plateau and decide the next medical step.
ContinueWeight-regain WebBook
Why weight can return after treatment changes and how to plan for maintenance.
ContinueGLP-1 Weekly
Physician-edited public education on the changing GLP-1 treatment landscape.
Continue
Patrick Oben, MD
Meet the board-certified obesity-medicine physician who reviews this page.
ContinueContact WellForm MD
Ask about retatrutide research, emerging options, and currently available care.
Continue
Interested in retatrutide?
Talk with a physician who specializes in obesity medicine
Patrick Oben, MD is board certified in Obesity Medicine and Internal Medicine and works with patients using comprehensive medical weight-management strategies. Obesity treatment at WellForm MD is physician led.
- Research context without hype
- Current treatment options
- No implication of current retatrutide prescribing
Authoritative sources
Time-sensitive claims follow Lilly’s Phase 3 releases
The percentages, populations, durations, and development-status statements on this page are drawn from Eli Lilly’s official TRIUMPH trial releases. Retatrutide remains investigational and is not FDA approved.
Medical review
Reviewed by Patrick Oben, MD
Board-certified physician authority for this educational service page.
Retatrutide remains an investigational medication. Information on this page is educational and reflects available clinical research; it is not an individual prescription or recommendation to use retatrutide. WellForm MD does not currently prescribe or sell retatrutide as an FDA-approved treatment.
- Board Certified in Obesity Medicine
- Board Certified in Internal Medicine
Reviewed September 15, 2026
Frequently asked questions about retatrutide
Direct answers to the questions people search most
These answers stay with the current evidence and the investigational status of the medicine.
A responsible next step
You do not have to wait for the next medication to start improving your health.
Contact WellForm MD to discuss retatrutide research, emerging obesity treatments, and the physician-led weight-loss options available today.
